Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cells

被引:26
作者
Finch, AR
Green, L
Hislop, JN
Kelly, E
McArdle, CA
机构
[1] Univ Bristol, Wellcome Labs Integrat Neurosci & Endocrinol, Bristol BS1 3NY, Avon, England
[2] Univ Bristol, Dept Pharmacol, Bristol BS1 3NY, Avon, England
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
D O I
10.1210/jc.2003-030787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
GnRH receptors (GnRH-Rs) mediate direct antiproliferative effects on hormone-dependent cancer cells. GnRH-Rs can be grouped according to ligand specificity (for GnRH-I and -II), and there is evidence that type II GnRH ligands and/or receptors can inhibit proliferation. Type I GnRH-Rs (e. g. human and sheep) lack the C-terminal tails found in other G protein-coupled receptors including type II GnRH-Rs (e. g. Xenopus; XGnRH-R). This underlies the remarkable resistance of type I GnRH-Rs to desensitization and may be important for chronic effects on proliferation. To test this, we have compared the antiproliferative effects of GnRH-Rs expressed in MCF7 breast cancer cells using recombinant adenovirus (Ad). Endogenous GnRH-Rs were not detected, but infection with Ad-expressing sheep GnRH-Rs (sGnRH-R) facilitated proliferation inhibition by Buserelin, and maximum inhibition required only 10,000-20,000 sGnRH-Rs. XGnRH-Rs were much less efficient at inhibiting proliferation and were internalized faster than sGnRH-Rs. Thus, the type II GnRH-R is less efficient at inhibiting proliferation, presumably because it is rapidly desensitized and/or internalized. Moreover, comparisons of human GnRH-R, sGnRH-R, and XGnRH-R, as well as chimeric receptors ( type I GnRH-Rs with C-terminal tails from XGnRH-Rs), revealed that C-terminal tail addition increases receptor expression and thereby increases the efficiency with which the vector facilitates the antiproliferative effect.
引用
收藏
页码:1823 / 1832
页数:10
相关论文
共 50 条
  • [1] Arencibia JM, 2000, INT J ONCOL, V16, P1009
  • [2] CLINICAL-APPLICATIONS OF GNRH AND ITS ANALOGS
    BARBIERI, RL
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1992, 3 (01) : 30 - 34
  • [3] Somatostatin receptors
    Benali, N
    Ferjoux, G
    Puente, E
    Buscail, L
    Susini, C
    [J]. DIGESTION, 2000, 62 : 27 - 32
  • [4] Pivotal role for the cytoplasmic carboxyl-terminal tail of a nonmammalian gonadotropin-releasing hormone receptor in cell surface expression, ligand binding, and receptor phosphorylation and internalization
    Blomenröhr, M
    Heding, A
    Sellar, R
    Leurs, R
    Bogerd, J
    Eidne, KA
    Willars, GB
    [J]. MOLECULAR PHARMACOLOGY, 1999, 56 (06) : 1229 - 1237
  • [5] Expression and anti-proliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells
    Choi, KC
    Auersperg, N
    Leung, PCK
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (10) : 5075 - 5078
  • [6] GONADOTROPIN-RELEASING HORMONE RECEPTORS - CHARACTERIZATION, PHYSIOLOGICAL REGULATION, AND RELATIONSHIP TO REPRODUCTIVE FUNCTION
    CLAYTON, RN
    CATT, KJ
    [J]. ENDOCRINE REVIEWS, 1981, 2 (02) : 186 - 209
  • [7] GONADOTROPIN-RELEASING-HORMONE AND ITS ANALOGS
    CONN, PM
    CROWLEY, WF
    [J]. ANNUAL REVIEW OF MEDICINE, 1994, 45 : 391 - 405
  • [8] ABSENCE OF RAPID DESENSITIZATION OF TBE MOUSE GONADOTROPIN-RELEASING-HORMONE RECEPTOR
    DAVIDSON, JS
    WAKEFIELD, IK
    MILLAR, RP
    [J]. BIOCHEMICAL JOURNAL, 1994, 300 : 299 - 302
  • [9] Incorporation of an additional glycosylation site enhances expression of functional human gonadotropin-releasing hormone receptor
    Davidson, JS
    Flanagan, CA
    Davies, PD
    Hapgood, J
    Myburgh, D
    Elario, R
    Millar, RP
    ForrestOwen, W
    McArdle, CA
    [J]. ENDOCRINE, 1996, 4 (03) : 207 - 212
  • [10] GONADOTROPIN-RELEASING-HORMONE (GNRH)-BINDING SITES IN HUMAN-BREAST CANCER CELL-LINES AND INHIBITORY EFFECTS OF GNRH ANTAGONISTS
    EIDNE, KA
    FLANAGAN, CA
    HARRIS, NS
    MILLAR, RP
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (03) : 425 - 432